Outcomes of surgical resection for pulmonary metastasis from ovarian cancer

Abstract

Background Due to its rarity, information on pulmonary metastasectomy for pulmonary metastasis from ovarian cancer is limited. Methods Cases of pulmonary metastasectomy for ovarian cancer were collected in a multi-institutional setting and the outcomes were analyzed. Results Among 1508 cases in which pulmonary resection was performed to treat pulmonary metastasis from tumors of various organs, 6 cases (0.4%) involved pulmonary metastasis from ovarian cancer. The mean age was 61 years (range, 39–75 years). The histological types were undifferentiated carcinoma in 2 patients, and clear cell adenocarcinoma, serous papillary cystadenocarcinoma, serous adenocarcinoma, and endometroid adenocarcinoma in 1 patient each. One patient (17%) had a history of liver metastasis at the time of pulmonary resection. The median disease-free interval was 22 months (range, 0 [synchronous]-188 months). The tumor was solitary in 5 patients (83%). The mean tumor size was 15 mm (range, 5–23 mm). All 6 patients underwent complete resection. The type of resection was wide wedge resection in 3 patients, segmentectomy in 2 patients, and lobectomy in 1 patient. Four patients (67%) received postoperative chemotherapy. Thus far, 4 patients (67%) have experienced recurrence after pulmonary resection. In terms of outcomes, 1 patient who had synchronous pulmonary metastasis with the primary tumor died in the early period after pulmonary resection, 1 patient is alive without recurrence after a short follow-up period (5 months), 3 patients have achieved mid- to long-term survival and are alive with disease (38–61 months), and 1 patient achieved long-term (61 months) disease-free survival. Conclusions Patients with pulmonary metastasis from ovarian cancer who fulfill the eligibility criteria for pulmonary metastasectomy are rare. Pulmonary metastasectomy for ovarian cancer can provide favorable outcomes in highly selected patients. Patients with synchronous pulmonary metastasis from ovarian cancer are not good candidates for pulmonary metastasectomy.

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis

“…Metastasis ovarian cancer is an advanced stage malignancy in which ovarian cancer cells spread from the primary tumor to distant areas such as the peritoneal cavity, omentum [37,38], liver [39], intestines, spleen [40], lungs [41,42], brain [43,44], and lymph nodes outside the abdomen [45]. Cancer cells must migrate and invade through the extracellular matrix into the blood vessels and lymphatic system, and then extravasate from the vessel to form distant sites [46].…”

Surgical treatment for pulmonary metastasis from ovarian cancer: a retrospective case series

“…Eighty-five percent of patients with OC recurrence present with intra-abdominal disease, resulting in death due to ascites or bowel obstruction [ 6 ]. Because PMs from OC are usually accompanied by extra-thoracic metastases and solitary PMs are rare, there have been only a few studies on radical surgery for PM from OC [ 7 ]. According to the 2016 Japanese statistics, only 69 (0.8%) of 8497 patients underwent PMT for OC [ 8 ].…”

Comparação da sobrevida dos pacientes portadores de metástase pulmonar e pleural submetidos à cirurgia diagnóstica e terapêutica

“…Informações sobre metástases pulmonares oriundas de câncer de ovário são limitadas devido à sua raridade. 13 A única paciente do estudo com carcinoma ovariano apresentava metástase pleural e, desde sua abordagem diagnóstica, permaneceu viva até o término do tempo de avaliação do trabalho (cerca de 10 meses).…”